The hereditary spastic paraplegias are a heterogeneous group of degenerative disorders that are clinically classified as either pure with predominant lower limb spasticity, or complex where spastic paraplegia is complicated with additional neurological features, and are inherited in autosomal dominant, autosomal recessive or X-linked patterns. Genetic defects have been identified in over 40 different genes, with more than 70 loci in total. Complex recessive spastic paraplegias have in the past been frequently associated with mutations in SPG11 (spatacsin), ZFYVE26/SPG15, SPG7 (paraplegin) and a handful of other rare genes, but many cases remain genetically undefined. The overlap with other neurodegenerative disorders has been implied in a small number of reports, but not in larger disease series. This deficiency has been largely due to the lack of suitable high throughput techniques to investigate the genetic basis of disease, but the recent availability of next generation sequencing can facilitate the identification of disease-causing mutations even in extremely heterogeneous disorders. We investigated a series of 97 index cases with complex spastic paraplegia referred to a tertiary referral neurology centre in London for diagnosis or management. The mean age of onset was 16 years (range 3 to 39). The SPG11 gene was first analysed, revealing homozygous or compound heterozygous mutations in 30/97 (30.9%) of probands, the largest SPG11 series reported to date, and by far the most common cause of complex spastic paraplegia in the UK, with severe and progressive clinical features and other neurological manifestations, linked with magnetic resonance imaging defects. Given the high frequency of SPG11 mutations, we studied the autophagic response to starvation in eight affected SPG11 cases and control fibroblast cell lines, but in our restricted study we did not observe correlations between disease status and autophagic or lysosomal markers. In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15. Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson’s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia. No plausible genetic cause was identified in 51% of probands, likely indicating the existence of as yet unidentified genes.
Introduction

The hereditary spastic paraplegias (HSPs) are a diverse group of neurodegenerative diseases with a prevalence of 2–7.4/100,000 in most populations (Erichsen et al., 2009; Blackstone, 2012; Noreau et al., 2014). They can be inherited in autosomal dominant, autosomal recessive or X-linked patterns with an age of onset that varies from early childhood to 70 years of age. HSP was first classified by Harding in the early 1980s (Harding, 1981), into pure or uncomplicated HSP, where lower limb spasticity occurs in isolation, frequently with bladder hyperactivity and mild impaired sense of vibration, and complex HSP that has prominent lower limb spasticity that is always accompanied by other neurological finding such as seizures, dementia, ataxia, deafness, extrapyramidal disturbance, orthopaedic abnormalities and peripheral neuropathy (Harding, 1981; Fink, 1993, 2013; Blackstone et al., 2011; Finsterer et al., 2012).

Mutations in over 40 genes have been found to cause HSP (de Bot et al., 2010, 2012; Dufke et al., 2012; Coutinho et al., 2013; Denora et al., 2013; Loureiro et al., 2013; Novarino et al., 2014). The most common cause of autosomal dominant spastic paraplegia are SPAST/SPG4 mutations, with patients presenting with a pure form of HSP (Schule and Schols, 2011; Finsterer et al., 2012; Fink, 2014; Noreau et al., 2014).

In the autosomal recessive complex HSP, the most frequent form seems to be associated with thinning of the corpus callosum (Boukhris et al., 2008; Finsterer et al., 2012) and it is mostly due to mutations in SPG11 (Stevanin et al., 2007; Paisan-Ruiz et al., 2008a, 2010b; Schule and Schols, 2011). It is also important to assess patients for rare causes of complex HSP such as enzyme deficiencies either biochemically or genetically (Wu et al., 2015). SPG11 is clinically characterized by slowly progressive spastic paraplegia and cognitive decline usually beginning before the second decade of life. Four less common distinct phenotypes have also been associated with SPG11 mutations, including Kjellin syndrome, which is a rare form of HSP with additional retinal manifestations (Puech et al., 2011; Nowak et al., 2014), slowly progressive amyotrophic lateral sclerosis (Orlacchio et al., 2010; Daoud et al., 2012), syndromes reminiscent of dystonia-parkinsonism (Paisan-Ruiz et al., 2010b; Kara et al., 2013) and syndromes with prominent L-DOPA responsive parkinsonism (Anheim et al., 2009a; Everett et al., 2012a). There have been reports of other types of spastic paraplegia being associated with improvement with L-DOPA (Mallaret et al., 2014). The increasing heterogeneity of spastic paraplegia and the clinical overlap seen with several other conditions suggests that there is still considerable genetic expansion to come in this group of disorders (Beetz et al., 2008; de Bot et al., 2012).

The clinical heterogeneity of HSP reflects the contribution of diverse cellular pathways to their pathogenesis (Crosby and Proukakis, 2002; Salinas et al., 2008; Blackstone et al., 2011). A number of proteins and pathways have been implicated including mitochondrial dysfunction (HSP60, spartin, paraplegin), microtubule trafficking and other membrane trafficking pathways (spastin, REEP1, atlsatin), lysosomal dysfunction (ZFYVE26), macroautophagy (spatscin, ZFYVE26, APSZ1) and lipid metabolism (FA2H, CYP7B1) (Salinas et al., 2008; Blackstone, 2012). The identification of macroautophagy is of particular interest, as autophagic dysfunction has been implicated in the pathogenesis of HSP (Chang et al., 2014), but also in a number of other neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and the spinocerebellar ataxias (Nixon, 2013). Given this mechanistic overlap and the presence of spasticity in other
neurodegenerative and movement disorder phenotypes, defects in these genetic pathways are likely to overlap, particularly within processes involved in mitochondrial functions (Schapira, 1999).

The aim of this study was 3-fold. First, to study the genotype–phenotype correlations and clinical features seen in a series of complex spastic paraplegia. We particularly focussed on SPG11, which makes up by far the largest group of complex spastic paraplegia cases. Second, to assess whether variants in genes that cause pure HSP, and other movement and neurodegenerative disorders are also involved in complex HSP. Third, following the identification of SPG11 mutations as the most common cause of complicated spastic paraplegia, we investigated spatacsin (the protein product of SPG11) through biochemical studies in a series of fibroblasts taken from patients and controls.

**Materials and methods**

**Patients**

A cohort of 97 patients that were referred to the National Hospital for Neurology and Neurosurgery (NHNN) for investigation or diagnosis were included in this study. Institutional review board (IRB)/ethical approval (UCLP – 99n102) and consent were obtained. We enrolled complex HSP patients and families where clinical details and DNA samples were available at the NHNN prior to 2015. From each family, we included only the proband. The inclusion criteria were slowly progressive HSP as the earliest manifestation or as the most significant clinical finding or the clinical reason for referral, along with at least one additional neurological feature such as: peripheral neuropathy, cognitive decline, epilepsy, skeletal/bony abnormalities, visual problems, parkinsonism, dystonia and ataxia (Fink, 1993, 2014). Nerve biopsy was carried out on one case and muscle biopsies on five cases (Houlden et al., 2001). Acquired or metabolic causes of HSP were excluded with an investigative work-up of MRI of the brain and spine, long chain fatty acids, white cell enzymes, routine and special blood tests for human T-lymphotropic virus (HTLV), Venereal Disease Research Laboratory test (VDRL), anti-nuclear antibodies (ANA)/extra nuclear antibodies (ENA)/anti-neutrophil cytoplasmic antibodies (ANCA), lupus and electromyography (EMG)/nerve conduction studies (NCS) and somatosensory evoked potentials (SSSEP)/visual evoked potentials (VEP)/auditory evoked potentials (AEP) often early in the diagnosis. When referring to overall severity of clinical signs we used mild, moderate, and severe. An example of this classification is with urinary problems where mild signs would be untreated urgency or frequency symptoms, moderate as therapeutically treated symptoms, and severe when a long-term catheter of different types is required. The overall degree of disability severity was measured with the modified Rankin score where mild is <2.0, moderate is 2.5–3.5 and severe ≥4. This scale is used for measuring the degree of disability in the daily activities of people who have suffered any causes of neurological disability. The scale runs from 0–6, ranging from perfect health without symptoms to death (Bonita and Beaglehole, 1988).

**Sanger sequencing**

Sanger sequencing of the entire coding region of SPG11 was carried out as previously described (Stevanin et al., 2007). Primer sequences and conditions are listed in Supplementary Tables 4 and 5. When a mutation was identified in a familial case, DNA samples from available family members were also analysed by Sanger sequencing to assess segregation and to determine the phase in cases with compound heterozygous mutations (Table 1 and Supplementary Table 1). SPG11 mutations were named following the transcript NM_025137.3. For one case (Case 52) in which SPG11 was negative for mutations, subsequent homozygosity mapping indicated FA2H as a candidate gene, which was found to be defective in this family. Multiplex ligation-dependent probe amplification (MLPA) was carried out using probes for SPG11 (P306 kit (MRC Holland)) in 42 patients negative for mutations in SPG11. A sample was considered negative when all probes were within 0.75–1.25 copies and standard quality control criteria were met. Variants identified using next generation sequencing were also confirmed through Sanger sequencing.

**Next generation sequencing**

A total of 66 patients were analysed that were either Sanger negative for SPG11 mutations, carried a single heterozygous mutation or were more recently identified cases. These were analysed using either the Illumina next generation clinical exome (Trusight one) sequencing (Illumina Inc) targeting 4813 genes where target genetic regions were covered at least 30 × in over 99% of the regions analysed, and seven patients underwent diagnostic Illumina whole exome sequencing, where coverage of the targeted genes was high though the Trusight clinical exome was superior. For data analysis, the raw data were mapped to the hg19 human reference assembly using the NovoAlign software, and polymerase chain reaction (PCR) duplicates were removed using the Picard software. Insertions–deletions (indels) and single nucleotide variants were called using the GATK package or SAMtools, and variants were confirmed through Sanger sequencing and were annotated using ANNOVAR, as previously described (Hersheson et al., 2013). In the preliminary filtering, variants with a minor allele frequency over 1/1000 in dbSNP (http://www.ncbi.nlm.nih.gov/snp/) or in the ExAC database (http://exac.broadinstitute.org/), synonymous variants and variants that were present in a segmental duplication region of over 95% were excluded. We focused on a subset of genes in which mutations have been previously associated with spastic paraplegia, neurodegeneration, ataxia, peripheral neuropathy, Parkinson’s disease and pallidopropymidal syndromes. Except in Case 48 where DNA was not available for Sanger, probable variants were confirmed through Sanger sequencing and were assessed for segregation in other affected or unaffected family members.

**Studies on patient-derived fibroblasts**

Skin biopsies were obtained from eight affected patients with homozygous or compound heterozygous mutations in SPG11 and nine healthy control subjects. Cases and controls were matched by gender, age and passage number (indicating the number of times a particular cell line has been subcultured and is used as a proxy for the age of the cells in culture) to the
<table>
<thead>
<tr>
<th>Proband number</th>
<th>Variant type</th>
<th>Variant</th>
<th>Ethnic origin</th>
<th>Consanguinity</th>
<th>Family history</th>
<th>Age at onset</th>
<th>Current age</th>
<th>Gender</th>
<th>Other features</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Compound heterozygous</td>
<td>c.275_284del, p.R93Afs*25/c.6899T &gt; C/p.L2300P</td>
<td>UK</td>
<td>No</td>
<td>Yes</td>
<td>10</td>
<td>18</td>
<td>M</td>
<td>Early inturning of the left foot</td>
</tr>
<tr>
<td>2</td>
<td>Homozygous</td>
<td>c.2146C&gt;T, p.Q716*</td>
<td>Pakistan</td>
<td>Yes</td>
<td>No</td>
<td>Child</td>
<td>26</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>3</td>
<td>Compound heterozygous</td>
<td>c.4132delA, p.S1378Afs*11/c.2843 + 1G&gt;T</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>N/A</td>
<td>27</td>
<td>No other features</td>
</tr>
<tr>
<td>4</td>
<td>Compound heterozygous</td>
<td>c.700G&gt;C, p.A2334P/ c.3146-1G&gt;C</td>
<td>Compound heterozygous</td>
<td>Italian/ Argentina</td>
<td>No</td>
<td>Yes</td>
<td>23</td>
<td>39</td>
<td>No other features</td>
</tr>
<tr>
<td>5</td>
<td>Homozygous</td>
<td>c.3809T&gt;A, p.V1270D</td>
<td>Turkish</td>
<td>Yes</td>
<td>Yes</td>
<td>12</td>
<td>18</td>
<td>M</td>
<td>Early inturning of the left foot</td>
</tr>
<tr>
<td>6</td>
<td>Homozygous</td>
<td>c.5769delT, p.S1923Rfs*28</td>
<td>Kenya/ India/ UK</td>
<td>Yes</td>
<td>Yes</td>
<td>20</td>
<td>33</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>7</td>
<td>Homozygous</td>
<td>c.866 + 1G&gt;A</td>
<td>Homozygous</td>
<td>Yes</td>
<td>No</td>
<td>4</td>
<td>35</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>8</td>
<td>Compound heterozygous</td>
<td>c.3623C&gt;T, p.P1208L/c.852_856delICTTAA, p.N284Kfs*14</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>19</td>
<td>25</td>
<td>Distant cousins also affected</td>
</tr>
<tr>
<td>9</td>
<td>Homozygous</td>
<td>c.6658_6659delAT, p.M2220Dfs*27</td>
<td>Turkish</td>
<td>Yes</td>
<td>Yes</td>
<td>21</td>
<td>42</td>
<td>F</td>
<td>Early inturning of the left foot</td>
</tr>
<tr>
<td>10</td>
<td>Homozygous</td>
<td>c.782C&gt;A, p.S261*</td>
<td>Cypriot</td>
<td>No</td>
<td>Yes</td>
<td>21</td>
<td>41</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>11</td>
<td>Homozygous</td>
<td>c.1492C&gt;T, p.Q498*</td>
<td>Egyptian</td>
<td>Yes</td>
<td>Yes</td>
<td>18</td>
<td>20</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>12</td>
<td>Compound heterozygous</td>
<td>c.2146C&gt;T, p.Q498*</td>
<td>Indian</td>
<td>Yes</td>
<td>Yes</td>
<td>18</td>
<td>20</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>13</td>
<td>Homozygous</td>
<td>c.1235C&gt;T, p.S412L</td>
<td>Egyptian</td>
<td>Yes</td>
<td>Yes</td>
<td>5</td>
<td>19</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>14</td>
<td>Homozygous</td>
<td>c.1492C&gt;T, p.Q498*</td>
<td>Egyptian</td>
<td>Yes</td>
<td>Yes</td>
<td>15</td>
<td>20</td>
<td>M</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>15</td>
<td>Compound heterozygous</td>
<td>c.3741dupA, p.P1248Tfs<em>17/ c.6091C&gt;T, p.R2031</em></td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>Yes</td>
<td>5</td>
<td>24</td>
<td>No other features</td>
</tr>
<tr>
<td>16</td>
<td>Homozygous</td>
<td>c.398delG, p.C133Lfs*22</td>
<td>Homozygous</td>
<td>Yes</td>
<td>Yes</td>
<td>17</td>
<td>35</td>
<td>F</td>
<td>Reduced visual acuity and slow tongue movements</td>
</tr>
<tr>
<td>17</td>
<td>Compound heterozygous</td>
<td>p.T206Nfs<em>13/p.W1524Lfs</em>22</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>14</td>
<td>23</td>
<td>Motor decline</td>
</tr>
<tr>
<td>18</td>
<td>Compound heterozygous</td>
<td>p.M245Vfs<em>2/p.Y1238Lfs</em>27</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>Teen</td>
<td>39</td>
<td>Motor decline</td>
</tr>
<tr>
<td>19</td>
<td>Homozygous</td>
<td>c.7115T&gt;A, p.L2372*</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>15</td>
<td>35</td>
<td>Motor decline</td>
</tr>
<tr>
<td>20</td>
<td>Homozygous</td>
<td>c.5769delT, p.S1923Rfs*28</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>Yes</td>
<td>14</td>
<td>19</td>
<td>Motor decline</td>
</tr>
<tr>
<td>21</td>
<td>Homozygous</td>
<td>c.315delC, p.A106Lfs*15</td>
<td>Compound heterozygous</td>
<td>India/ UK</td>
<td>Yes</td>
<td>Yes</td>
<td>17</td>
<td>29</td>
<td>Motor decline</td>
</tr>
<tr>
<td>22</td>
<td>Compound heterozygous</td>
<td>c.689_693delGAT, p.I2298del/ c.4237delinsTA, p.V1413Yfs*14</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>Yes</td>
<td>13</td>
<td>26</td>
<td>Motor decline</td>
</tr>
<tr>
<td>23</td>
<td>Homozygous</td>
<td>c.6891_6893delGAT, p.I2298del/ c.4237delinsTA, p.V1413Yfs*14</td>
<td>Homozygous</td>
<td>UK</td>
<td>No</td>
<td>Yes</td>
<td>13</td>
<td>26</td>
<td>Motor decline</td>
</tr>
<tr>
<td>24</td>
<td>Homozygous</td>
<td>c.733_734delAT, p.M245Vfs*2</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>16</td>
<td>25</td>
<td>Motor decline</td>
</tr>
<tr>
<td>25</td>
<td>Compound heterozygous</td>
<td>c.1348dupA, p.H505Nfs<em>26/ c.5454_5455delAG, p.E1819Afs</em>10</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>Yes</td>
<td>10</td>
<td>50</td>
<td>Motor decline</td>
</tr>
<tr>
<td>26</td>
<td>Homozygous</td>
<td>c.5399_5407delAGATinsTGGAGGAG, p.Q1800Lfs*31</td>
<td>Homozygous</td>
<td>Pakistan</td>
<td>Yes</td>
<td>Yes</td>
<td>13</td>
<td>33</td>
<td>Motor decline</td>
</tr>
<tr>
<td>27</td>
<td>Compound heterozygous</td>
<td>c.5623C&gt;T, p.Q1875Y/c.7158del, p.Q2387Tfs*6</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>27</td>
<td>33</td>
<td>Motor decline</td>
</tr>
<tr>
<td>28</td>
<td>Homozygous</td>
<td>c.267G&gt;A, p.W898*</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>Yes</td>
<td>No</td>
<td>4</td>
<td>28</td>
<td>Motor decline</td>
</tr>
<tr>
<td>29</td>
<td>Compound heterozygous</td>
<td>c.3373_3383delAT, p.M245Vfs*12</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>15</td>
<td>22</td>
<td>Motor decline</td>
</tr>
<tr>
<td>30</td>
<td>Homozygous</td>
<td>c.4438G&gt;T, p.E1495*</td>
<td>Homozygous</td>
<td>India</td>
<td>Yes</td>
<td>Yes</td>
<td>12</td>
<td>25</td>
<td>Motor decline</td>
</tr>
<tr>
<td>31</td>
<td>Compound heterozygous</td>
<td>c.4751G&gt;C, p.D1584Gfs*22</td>
<td>Compound heterozygous</td>
<td>UK</td>
<td>No</td>
<td>No</td>
<td>15</td>
<td>22</td>
<td>Motor decline</td>
</tr>
<tr>
<td>32</td>
<td>Compound heterozygous</td>
<td>c.5769delT, p.S1923Rfs*28</td>
<td>Compound heterozygous</td>
<td>Kenya/ UK</td>
<td>Yes</td>
<td>Yes</td>
<td>10</td>
<td>30</td>
<td>Motor decline</td>
</tr>
</tbody>
</table>

* = nonsense; del = deletion; n/a = not available.

Other family members available for segregation.

Potentially related to patient number 6.

SPG11 variants were labelled according to the transcript NM_025137.3 using the standard mutation nomenclature used in molecular diagnostics (Ogino et al., 2007). See main text for discussion on pathogenicity.
extent possible. Details of the cell lines used in this study are summarized in Supplementary Table 6. Fibroblasts were grown as previously described (Tucci et al., 2014) and reverse transcriptase PCR was used to assess the transcription of SPG11 in fibroblast cell lines (Cottenie et al., 2014). Primers spanning exons 7–8 of SPG11 were designed to avoid non-specific amplification of genomic DNA. GAPDH was used as a housekeeping gene (see Supplementary Tables 4 and 5 for primer sequences and conditions). Autophagy was assessed through western blot analysis of autophagy and lysosomal markers including LAMP1, LC3, p62, HSP70 as previously described (Manzoni et al., 2013) (Supplementary material). LAMP1 is a structural component of lysosomes and consequently it can be used as a marker for lysosomal size and number. LC3-II is considered a marker for macroautophagy (Tanida et al., 2008). p62 is a cargo protein that binds to proteins targeted to autophagosomes for degradation (Mizushima and Komatsu, 2011). The HSP70 family of proteins, in particular Hsc70, participate in chaperone-mediated autophagy promoting internalization of targeted proteins in lysosomes through LAMP2A (Agarraberes et al., 1997). Among the substrates of mTOR phosphorylation, we selected P70S6K as a marker of efficient starvation. The phosphorylated form of P70S6K decreases during starvation and can be used as a marker for the efficiency of the starvation experiments. P70S6K is a phosphorylation substrate only for mTOR (Nixon, 2013) and is thus specific to check for mTOR block by starvation. Each experiment was repeated at least three times.

Results

Genetic findings

A likely pathogenic genetic defect was identified in 48/97 (49%) of complex HSP patients (Fig. 1A, Table 1 and Supplementary Table 1). This does not include variants of unknown significance. Homozygous or compound heterozygous mutations in SPG11 were identified in 30.9% of patients (30/97), which is the largest series to date and the most common cause of disease in complex HSP in the UK (Fig. 1D). No cases carrying copy number variants within the SPG11 locus were identified using MLPA. The vast majority of SPG11 mutations were non-sense or frameshift changes. Interestingly no homozygous mutations are present in the ExAC database (http://exac.broadinstitute.org/gene) of over 100,000 control population cases, indicating that loss of function mutations are not tolerated in the general population. SPG11 was followed by SPG7 (5/97), FA2H/SPG35 (4/97), ZFYVE26/SPG15 (2/97) and single families with SPG3a (ATL1), SPG8 (KIAA0196), SACS and SPG5 (CYP7B1) (Fig. 1A). Variants within genes associated with Parkinson’s disease (PARK9; ATP13A2), neuronal ceroid lipofuscinosis (NCL; TPP1) and hereditary neuropathy (DNMT1) were also identified. From the variants identified, nine in SPG11, and one in FA2H and one in KIAA0196 had been previously reported (Paisan-Ruiz et al., 2008a, b, 2010b; Dick et al., 2010; Everett et al., 2012a; Bettencourt et al., 2013; Nowak et al., 2014). Variants in other non-SPG11 genes were not found in the ExAC population control database at a frequency of <10 heterozygous cases, except for Cases 38, 39, 44 and 48. Case 48 carries two CYP7B1 likely compound heterozygous variants, where one (p.R486C) is reported as pathogenic (Goizet et al., 2009) and present in 82 ExAC population individuals and the other variant (c.122 +2T>C) is absent in this dataset. Cases 38, 39 and 44 carry the SPG7 variant p.A510V, which was present in 57 individuals on the ExAC database but has previously been multiply-reported as pathogenic (Choquet et al., 2015; Pfeffer et al., 2015). In addition, the SPG7 variants we identified and those previously reported, often had a similar phenotype of spastic ataxia but we also highlight the prominent ophthalmoplegia (Choquet et al., 2015). Variants of unknown significance were also identified (Supplementary Table 3) and are discussed in detail in the Supplemental material and a summary of the negative case details is given in Supplementary Fig. 3.

Clinical findings

In the 97 individuals identified with complex HSP, the clinical phenotypes primarily consisted of HSP with ataxia as the most common association, followed by cognitive decline, neuropathy, seizures, dystonia, parkinsonism and rarely other features. The mean age of onset was 16 years, ranging from age 3 to 39 years. Summary clinical information for the complex HSP cases is given in Table 1 and Supplementary Tables 1–3.

SPG11

General features

SPG11 mutations were identified in 30 probands. We removed one proband that may be distantly related to Family 6 because they come from the same ethnic community group and have the same mutation. In general, SPG11 onset was in childhood/early teenage years (mean age at onset 14.3 years, range 4–27 years), with walking problems and spasticity, severe bladder problems, ataxia, neuropathy, parkinsonism and/or cognitive problems (Table 1 and Fig. 1B).

Atypical presentation

Some patients presented in an atypical way, such as the proband from Family 5 (Table 1) who exhibited a very mild phenotype including toe walking, brisk reflexes and extensor plantars at the age of 12 years with little disease progression by the age of 22 years. His aunt had typical SPG11 features in her 30s. Case 10 had spastic paraplegia with severe optic atrophy and visual problems. The proband from Family 6 had a severe and treatment-resistant oromandibular dystonia. Interestingly his sister had a relatively mild phenotype but his distant community cousins had a typical severe SPG11. The longest surviving case
carrying an SPG11 mutation is currently 50 years of age and has severe complex HSP as well as severe cognitive decline and late-onset seizures, similar to the deceased sibling (Family 25).

Genotype–phenotype correlations
There were no clear genotype–phenotype correlations that we could define although Case 5 with the mildest clinical and MRI phenotype had a homozygous missense mutation, and progressed relatively slowly.

Figure 1 Overview of mutations identified in spastic paraplegia genes. (A) Pie chart showing the frequency of mutations in spastic paraplegia genes identified. The figures in brackets represent the number and percentage of cases respectively. (B) Frequencies of clinical features that were present in addition to the spastic paraplegia in SPG11 probands. (C) Frequencies of clinical features that were present in addition to spastic paraplegia in the spastic paraplegia patients with other mutations. In B and C the figures in brackets refer to the number of cases. (D) Diagram of the SPG11 gene with mutations identified in the present study. Grey arrows indicate novel and black arrows indicate previously reported mutations.

MRI findings
The MRI findings in SPG11 patients are presented in Fig. 2A; images were compared to controls. Patients with mild-to-moderate disease had minimal corpus callosum thinning while severe SPG11 patients had more severe thinning as well as cerebral atrophy. When the disease is severe the corpus callosum remains at a static state and does not seem to change over time, as in Supplementary Fig. 1, although these are longitudinal data from only two cases.
Figure 2  MRI features in patients with complex HSP. (A) Sagittal MRI of SPG11 patients showing progressive thinning of the corpus callosum and cerebral atrophy, which correlates with the progression of clinical features. (i) MRI from a healthy individual with labelling of the different parts of the corpus callosum. (ii) Case 5 at age 18 (mild disease). (iii) Case 8 at age 22 (mild-moderate disease). (iv) Case 17 at age 23.
SPG7

General features

Five families were identified with SPG7 variants (Families 35, 37–39 and 44). In the Kenyan family (Family 35), presentation was in the 30s with progressive spasticity and ataxia. In the other families, disease onset was earlier, often with an initial diagnosis of cerebral palsy or poor coordination. Associations of SPG7 variants with optic atrophy, neuropathy and ophthalmoplegia were also identified.

SPG35 (FA2H)

General features

Four families with FA2H (SPG35) variants were identified (Families 32, 34, 51 and 52; Supplementary Table 1), of which three carried compound heterozygous variants and one a homozygous variant. In Families 32, 51 and 52 segregation was shown in affected and unaffected members. The age of onset varied between 5 and 22 years with the initial presentation being progressive balance problems and toe walking. Spastic quadriplegia was present on examination, along with early bladder problems, dysarthria, dysphagia and limb ataxia. One family had severe ophthalmoplegia and skew defect, seizures were present in two families, and two families had optic atrophy.

Interestingly, the dysarthria progressed rapidly in all cases, developing into an early anarthria which is different than SPG11 and 15 and an important clinical point to note.

MRI findings

MRI findings ranged from atrophy of the cerebellum and brain stem to more significant findings that also included corpus callosum atrophy, cortical atrophy and white matter abnormalities (Fig. 2C).

ZFYE26/SPG15

General features

Two cases with homozygous mutations in ZFYVE26/SPG15 were identified. These cases presented and progressed in a very similar way to SPG11, although the neuropathy was greater (Supplementary Table 1 and Figs 2B and 4). In the non-SPG11 cases there were also additional neurological features, as shown in Fig. 1C.

Atypical presentation

In addition, Case 33 has adducted thumbs that were very similar to those seen in mental retardation, aphasia, shuffling gait and adducted thumbs (MASA) syndrome (SPG1), an X-linked spastic paraplegia syndrome that is caused by mutations in the LICAM gene (Jouet et al., 1994; Vits et al., 1994) (Fig. 3).
ATP13A2

General features
The proband from Family 41 presented at 18 years old with spastic quadriplegia, falls, cognitive decline, bilateral pes cavus and ataxia. Eye signs were prominent, with bilateral divergent squints and nystagmus on lateral gaze and reduced upgaze. He was the product of a consanguineous marriage. Genetic testing revealed novel heterozygous variants in ATP13A2 (c.3017_3019del; p.1006_1007del), which are near/in the transmembrane helix and not present in over 100,000 ExAC controls.

MRI findings
The MRI showed cerebral atrophy and subtle abnormalities of the basal ganglia. An l-DOPA trial initially helped patient symptoms but there were no signs of objective or long-term improvement.

TPP1

General features
In Family 43, which was found to carry a variant in TPP1, the proband initially presented with walking problems, progressive spastic paraplegia and poor intellectual function at the age of 11 years old, with a past history of two seizures. At the age of 31 she had severe spasticity in her limbs, along with a bulbar palsy, dystonic neck posturing and also severe cognitive problems. There is no family history.

MRI and additional tests
Her MRI showed cerebral atrophy and thinning of the corpus callosum (Supplementary Fig. 1). There were background EEG abnormalities but the muscle and skin biopsy was normal. She responded to l-DOPA for 5 years that improved her mobility temporarily, though screening for variants in GCH1 was negative.

Nerve conduction studies, EMG and nerve biopsy
Nerve conduction studies and EMG were minimally helpful in defining some types of HSP (Supplementary Table 2). One SPG11 case was abnormal along with both ZFYVE26/SPG15 cases. Similarly, a nerve biopsy was also abnormal in ZFYVE26/SPG15 [Case 33, Fig. 2B(iv–vi)].

Characterization of the autophagic response in SPG11 patient-derived fibroblasts
Reverse transcription PCR on RNA extracted from fibroblast cell lines from cases and controls showed that SPG11 is expressed in this tissue at levels similar to the housekeeping gene GAPDH (Fig. 5). We studied the different autophagy and lysosomal markers in fibroblasts under basal conditions (Supplementary Figs 4–7) and after induction of autophagy by starvation (Fig. 6A and B, and Supplementary Figs 4–7). We did not observe significant correlations between disease status and autophagic/lysosomal markers, although there was a trend towards increased LC3-II in cases.

Discussion
Here we describe the genetic analysis of 97 complex HSP probands using a combination of Sanger and next generation sequencing. We identified the genetic cause of the disease in 49% of the patients studied. SPG11 defects were found to be by far the commonest cause of complex HSP in the UK, accounting for 30.9% of cases and being the largest series reported to date. This is higher than previous reports (Stevanin et al., 2007, 2008; Erichsen et al., 2008; Paisan-Ruiz et al., 2008a; Anheim et al., 2009a; Orlen et al., 2009; Schule et al., 2009; Orlacchio et al., 2010; Southgate et al., 2010; Guidubaldi et al., 2011; Daoud et al., 2012; Cao et al., 2013), but the frequency is in-line with a recent study from Italy (26.2%) (Pensato et al., 2014). Variants in SPG7 represented 6% and the frequency of FA2H was also higher that previous reports at 4% (Pensato et al., 2014). ZFYVE26/SPG15 was infrequent in our cohort with only two families although Family 33 extends the clinical features associated with variants in this gene (Figs 3 and 4). The discrepancy in the variants frequency is likely population-specific and possibly due to the use of next generation sequencing in our report, in contrast to previous candidate gene-based studies. In addition, our cohort was a multi-ethnic population, whereas those in previous reports were ethnically more homogeneous, focusing on the Mediterranean basin or Caucasian populations.

The core clinical presentation of SPG11 was consistent with previous reports, but a number of other neurological features were identified (Fig. 1B). The age of onset ranged between 4 and 27 years, most frequently presenting with walking problems due to lower limb spasticity and later ataxia and foot deformities. Other progressive neurological features include parkinsonism that often responded to l-DOPA, axonal neuropathy and learning difficulties (Fig. 1B). In addition SPG11 cases tended to remain mobile up until 30 years, with a mean modified Rankin score of < 3. Patients aged over 30 years were more significantly disabled and completely dependent when over 40 years (Supplementary Fig. 2) (Patel et al., 2012).

One SPG11 patient with extreme visual problems was found to have Kjellin syndrome, although optic atrophy and retinal signs were generally rare in this HSP (Puech et al., 2011; Nowak et al., 2014). The majority of patients had white matter abnormalities and corpus callosum thinning on MRI, though this feature was not restricted to SPG11 mutations as we also observed it in ZFYVE26/SPG15 and
Figure 4 Morphological findings of one nerve and four muscle biopsies in five genetically characterized patients with HSP. Patient with ZFYVE26/SPG15 mutation (A and C) and control individual (B and D). SPG11 mutation (E), SPG7 mutation (F and G). Semi-thin resin preparations stained with methylene blue azure—basic fuchsin (A and B) show a reduction of large myelinated fibre density in the patient’s biopsy, compared with a biopsy from age-matched control. Large fibre loss is further confirmed by electron microscopy (C and D), while unmyelinated fibres are better preserved. There is no evidence of active axonal degeneration, regeneration or demyelination and the overall picture is that of chronic axonal neuropathy. The muscle biopsies from three patients investigated for signs of denervation show varied appearances. In the biopsy from the patient with a known SPG11 mutation (E) there is predominance of type 1 fibres (yellow arrow, ATP pH4.3). In one patient with SPG7 mutation (F) the most significant finding in the muscle biopsy is that of several COX-deficient fibres (red arrows) seen on combined COX-SDH preparation. In another patient with SPG7 mutation (G) the biopsy confirms neurogenic change with evidence of previous denervation with re-innervation (blue arrow indicates a group of type 1 fibres, ATP pH4.3). Scale bars: A, B and E–H = 40 μm; C and D = 5 μm.
**FA2H** variant carriers (Fig. 2A–C). Although in a relatively low number of patients, **SPG11** was associated with parkinsonism in five cases and was L-DOPA-responsive in three cases, indicating a role for the basal ganglia in HSP, suggesting that this medication should be considered in such cases, indicating a role for the basal ganglia in HSP, suggesting that this medication should be considered in **SPG11**-associated HSP. Two patients had a positive family history of essential tremor (Case 6) and Parkinson’s disease (Case 15), an observation that has previously been made in other variants that are not likely to contribute to the pathogenesis of **SPG11** mutations, contrary to other genetic forms of HSP (Proukakis et al., 2009; Crimella et al., 2004; Anheim et al., 2009; Bras et al., 2012). **ATP13A2** variants are associated with heterogeneous phenotypes including Kufor-Rakeb syndrome (Ramirez et al., 2006), NCL (Bras et al., 2012) and Parkinson’s disease (Malakouti-Nejad et al., 2014). Kufor-Rakeb syndrome clinically partially overlaps with HSP as patients often exhibit spasticity in addition to dystonia, parkinsonism and mental retardation (Ramirez et al., 2006). Patients with NCL caused by **ATP13A2** variants have similar clinical features with Kufor-Rakeb syndrome patients (Bras et al., 2012). NCL syndromes are characterized by accumulation of autofluorescent material, a feature that is not characteristic of HSP, though biopsy material was not as yet available for our HSP patient with the **ATP13A2** variant. In general, these findings suggest an overlap between spastic paraplegias and numerous other neurodegenerative diseases, an observation that has already been made through protein network analyses (Novarino et al., 2014). Our results also highlight the worldwide distribution of mutations in genes associated with autosomal recessive spastic paraplegias and these data indicate that ethnic background should not be a criterion to prioritize patients for genetic testing. These findings expand the clinical spectrum of complex spastic paraplegias and underline the clinical overlap with other diseases such as spinocerebellar ataxias and dystonia-parkinsonism and the difficulty of prioritizing genetic testing in these patients where functional investigation should ideally be applied to all likely pathogenic variants. Thus, the use of next generation sequencing-based panels containing a series of candidate genes is becoming exceedingly important in the genetic work-up of such patients.

Numerous variants of unknown significance were detected, which is a common problem associated with the application of high throughput approaches to study the genetic basis of diseases (MacArthur et al., 2014). These cases could represent a broadening of the clinical phenotype but future studies are necessary to clarify this. We did not identify definite or probable variants in any of the

**Figure 5** Reverse transcription PCR to assess **SPG11** mRNA expression in fibroblasts. Wide expression is seen across **SPG11** affected and control fibroblasts. Numbers in red are **SPG11** affected cases from Table I and Supplementary Table I. Letters in blue are controls from Supplementary Table I. GAPDH = housekeeping gene glyceraldehyde 3-phosphate dehydrogenase.
Figure 6  Analysis of markers for autophagy and lysosomal function in human fibroblast cells. (A) Fibroblast protein expression levels of LAMP1 and LC3 as compared to beta actin in SPG11 affected and control fibroblasts after starvation induced autophagy (overnight serum starvation, followed by 2.5 h amino acid starvation in low glucose). (B) Fibroblast protein expression levels of p62 and HSP70 as compared to beta actin in SPG11 affected and control fibroblasts after starvation induced autophagy (overnight serum starvation, followed by 2.5 h amino acid starvation in low glucose).
genes studied in 51% of the cases. This observation indicates that there are probably additional rare variants in novel genes causing spastic paraplegia that have not yet been discovered. Alternatively, it is possible that other types of genetic mechanisms such as mosaicism (Proukakis et al., 2013), di- or polygenic inheritance and imprinting defects could be responsible for the disease in a proportion of patients.

The functional role of spatacsin is unknown, though candidate gene pathway analysis has implicated autophagic dysfunction in the pathogenesis of the disease (Chang et al., 2014). We attempted to replicate previous findings linking spatacsin with the regulation of autophagy using a cohort of patient-derived fibroblasts. Although a trend towards an increase in LC3-II was present in cases, no significant changes in autophagy markers of disease were identified in these cells under the experimental conditions used herein to assess autophagy. It should be noted, however, that interpretation of results from functional studies on patient fibroblasts requires caution, as interindividual variability is an important limitation that could potentially mask real effects of mutations or, alternatively, lead to false positives. Further studies with an increased number of cases and controls are therefore required to determine whether spatacsin has a role in the regulation of autophagy, including detailed analysis of autophagic flux following treatment with bafilomycin. Such functional characterization of spatacsin will be crucial to understanding the mechanisms underlying degeneration in these cases, as well as developing potential therapies. While outside the scope of this present study, this should be a priority for the research community in the future.

Acknowledgements

The authors would like to thank all the participants of the study for their essential help with this work.

Funding

This study was supported by the Medical Research Council (MRC UK), The Rosetrees Trust, The Wellcome Trust [equipment and the Synaptopathies strategic award (104033)] and The Brain Research Trust (BRT) The Muscular Dystrophy Association (MDA), Muscular Dystrophy UK, The UK HSP Society and the EU FP7/2007-2013 under grant agreement number 2012-305121 (NEUROMICS). We are also supported by the HSP society UK, The MRC Centre for Neuromuscular Diseases (G0601943), EMBO Long term fellowship ATLF-815-2014 (EK), The National Brain Appeal Small Acorns Fund, Parkinson’s UK fellowship F1002 (PAL), MRC grant MR/L010933/1 (PAL) and we are also supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC).

Supplementary material

Supplementary material is available at Brain online.

References


